IntoCell Inc is a Korea-based company principally engaged in the development of antibody-drug conjugate (ADC) platform technology. The Company mainly develops ortho-hydroxy-protected aryl sulfate (OHPAS) platform technology, which is a linker connecting to drugs. In addition, the Company also develops platform technologies such as payload modification technology (PMT) platform technology, which reduces drug uptake into normal cells, and proprietary drug technology used in ADC development.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
24/07/26	₩19,750.00	-15.60%	155,994
23/07/26	₩23,400.00	+15.84%	194,543
22/07/26	₩20,200.00	+2.18%	49,166
21/07/26	₩19,770.00	-3.56%	44,272

End-of-day quote Korea S.E.

More quotes

Income Statement and Estimates

More financial data

Annual profits - Rate of surprise

Company calendar

End-of-day quote Korea S.E. Other stock markets 24/07/2026			5-day change	1st Jan Change
19,750.00 ^KRW	-15.60%		-10.23%	-65.59%

07-23	Samsung EpiS Unit Signs Cancer Drug Development, Commercialization Deal with IntoCell	MT
12-22	IntoCell, Inc.(KOSDAQ:A287840) added to S&P Global BMI Index	CI

Market Cap	297B 203M 178M 166M 152M 286M 19.56B 291M 1.97B 770M 9.62B 763M 746M 33.26B	P/E 2024 *	-	P/E 2025	-77.1x
Enterprise Value	276B 189M 166M 154M 142M 266M 18.21B 270M 1.83B 716M 8.95B 710M 694M 30.95B	EV / Sales 2024 *	-	EV / Sales 2025	365,559,272x
Free-Float	78.73%	Yield 2024 *	-	Yield 2025	-

07-23	Samsung EpiS Unit Signs Cancer Drug Development, Commercialization Deal with IntoCell	MT
12-22	IntoCell, Inc.(KOSDAQ:A287840) added to S&P Global BMI Index	CI
31/10/25	IntoCell Inc. and Xcellon Biologics Announce MOU to Expand Access to Next-Generation ADC Technologies	CI
30/10/25	Piramal Pharma Solutions Formalizes Partnership with IntoCell, Expanding Its Payload-Linker Platform and Bioconjugate Capabilities	CI

1 day	-15.60%
1 week	-10.23%
Current month	-17.02%
1 month	-6.18%
3 months	-50.38%
6 months	-63.43%
Current year	-65.59%

IntoCell, Inc. Share Price

Stocks

A287840

KR7287840003

Biotechnology & Medical Research

Valuation: IntoCell, Inc.

Chart: IntoCell, Inc.

Latest news : IntoCell, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: IntoCell, Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

1 week	18,800	23,500
1 month	18,800	25,400
Current year	18,800	63,500
1 year	18,800	74,900
3 years	18,800	74,900
5 years	18,800	74,900
10 years	18,800	74,900

Manager	Title	Age	Since
Tae-Kyo Park CEO	Chief Executive Officer	66	31/03/2015
Young-Seok Seo DFI	Director of Finance/CFO	68	31/05/2019
Yo-Seop Yu CTO	Chief Tech/Sci/R&D Officer	58	31/03/2021

Director	Title	Age	Since
Young-Seok Seo BRD	Director/Board Member	68	19/03/2020
Tae-Kyo Park BRD	Director/Board Member	66	31/03/2015
Yo-Seop Yu BRD	Director/Board Member	58	31/03/2021

Date	Insider	Type	Main position	Quantity	% Market Cap.
15/07/25	Tae-Kyo Park	Buy	Founder	10,000	0.0674%
15/07/25	Tae-Kyo Park	Buy	Founder	26,000	0.1751%
28/05/25	Jae-Hee Choi	Free		40,400	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
INTOCELL, INC.	-15.60%	-10.23%	-24.33%	-	203M
LONZA GROUP AG	+1.07%	-3.49%	-3.35%	+11.75%	46.86B
REVOLUTION MEDICINES, INC.	+0.25%	+1.65%	+399.22%	+647.65%	40.23B
BEONE MEDICINES AG	-0.27%	+4.45%	+11.81%	+60.81%	36.23B
IQVIA HOLDINGS INC.	+0.35%	+0.87%	+4.46%	-10.31%	34.72B
CELLTRION, INC.	+3.14%	+1.02%	+4.76%	+43.00%	27.89B
MEDPACE HOLDINGS, INC.	-0.73%	+11.84%	+34.39%	+134.44%	16.79B
ASCENDIS PHARMA A/S	+0.47%	-2.74%	-	-	16.74B
EUROFINS SCIENTIFIC SE	+0.42%	-5.52%	-3.43%	+9.10%	13.12B
ICON PUBLIC LIMITED COMPANY	-2.68%	-2.49%	-11.36%	-34.51%	12.7B
Average	-1.36%	+0.38%	+45.80%	+107.74%	24.55B
Weighted average by Cap.	+0.46%	+0.91%	+74.33%	+138.21%

	2024	2025
Net sales	2.91K 1.99 1.75 1.62 1.49 2.8 191.57 2.84 19.29 7.54 94.18 7.47 7.31 325.64	2.3K 1.57 1.38 1.29 1.18 2.22 151.61 2.25 15.27 5.97 74.54 5.91 5.78 257.72
Net income	-9.91B -6.79M -5.96M -5.54M -5.09M -9.56M -654M -9.71M -65.84M -25.72M -321M -25.48M -24.93M -1.11B	-10.6B -7.26M -6.38M -5.93M -5.44M -10.23M -699M -10.38M -70.43M -27.51M -344M -27.26M -26.67M -1.19B
Net Debt	-2.15B -1.47M -1.29M -1.2M -1.1M -2.07M -142M -2.1M -14.25M -5.57M -69.57M -5.52M -5.4M -241M	-20.59B -14.1M -12.38M -11.51M -10.57M -19.85M -1.36B -20.16M -137M -53.42M -667M -52.92M -51.78M -2.31B